Literature DB >> 2903159

A surface component on GH3 pituitary cells that recognizes transforming growth factor-beta, activin, and inhibin.

S Cheifetz1, N Ling, R Guillemin, J Massagué.   

Abstract

We have examined the ability of various forms of activin and inhibin, which are structurally related to transforming growth factor-beta (TGF-beta), to interact with various types of cell surface TGF-beta binding sites. Activin AB, inhibin A, and inhibin B were unable to compete with 125I-TGF-beta 1 for binding to the TGF-beta receptor types I, II, or III that coexist in human skin fibroblasts, rat liver epithelial cells, and mink lung epithelial cells. In contrast, activins and inhibins effectively competed for TGF-beta 1 binding to GH3 rat pituitary tumor cells. Binding of TGF-beta 1 to GH3 cells was mediated by about 2700 sites/cell with a Kd = 90 pM. Affinity labeling of these GH3 binding sites by cross-linking to 125I-TGF-beta 1 yielded 70-74-kDa labeled complexes distinct from previously identified TGF-beta binding components. Labeling of these 70-74-kDa components with 125I-TGF-beta 1 was inhibited by TGF-beta 1, TGF-beta 2, activin AB, and inhibin B at concentrations in the high picomolar to low nanomolar range, but it was not significantly affected by other polypeptide hormones and growth factors tested. The 70-74-kDa labeled GH3 components represent a novel type of cell surface TGF-beta binding protein that is unique in its ability to recognize various other members of the TGF-beta family of bioactive polypeptides.

Entities:  

Mesh:

Substances:

Year:  1988        PMID: 2903159

Source DB:  PubMed          Journal:  J Biol Chem        ISSN: 0021-9258            Impact factor:   5.157


  15 in total

Review 1.  The role of growth factors in the pituitary.

Authors:  S Ezzat; S Melmed
Journal:  J Endocrinol Invest       Date:  1990-09       Impact factor: 4.256

Review 2.  The Discovery and Early Days of TGF-β: A Historical Perspective.

Authors:  Harold L Moses; Anita B Roberts; Rik Derynck
Journal:  Cold Spring Harb Perspect Biol       Date:  2016-07-01       Impact factor: 10.005

3.  Reciprocal inhibition of binding between interleukin 3 and granulocyte-macrophage colony-stimulating factor to human eosinophils.

Authors:  A F Lopez; J M Eglinton; D Gillis; L S Park; S Clark; M A Vadas
Journal:  Proc Natl Acad Sci U S A       Date:  1989-09       Impact factor: 11.205

4.  Activin-A binding and biochemical effects in osteoblast-enriched cultures from fetal-rat parietal bone.

Authors:  M Centrella; T L McCarthy; E Canalis
Journal:  Mol Cell Biol       Date:  1991-01       Impact factor: 4.272

5.  Expression and localization of inhibin/activin and activin receptors in GH3 cells, a rat pituitary adenocarcinoma cell line.

Authors:  C Ying; Z Zhang; G Huang; S Q Li; S Y Ying
Journal:  J Endocrinol Invest       Date:  1996-01       Impact factor: 4.256

6.  Gene expression of transforming growth factor-beta 1 and its type II receptor in giant cell tumors of bone. Possible involvement in osteoclast-like cell migration.

Authors:  M H Zheng; Y Fan; S J Wysocki; A T Lau; T Robertson; M Beilharz; D J Wood; J M Papadimitriou
Journal:  Am J Pathol       Date:  1994-11       Impact factor: 4.307

7.  Expression and Regulation of Transforming Growth Factor B1 in Cultured Normal and Neoplastic Rat Pituitary Cells.

Authors:  Xiang Qian; Long Jin; Ricardo V. Lloyd
Journal:  Endocr Pathol       Date:  1996       Impact factor: 3.943

8.  Inhibin and the regulation of bone mass.

Authors:  Dana Gaddy
Journal:  Curr Osteoporos Rep       Date:  2008-06       Impact factor: 5.096

Review 9.  Transforming growth factor beta (TGF-beta) in inflammation: a cause and a cure.

Authors:  S M Wahl
Journal:  J Clin Immunol       Date:  1992-03       Impact factor: 8.317

10.  Regulation of follistatin messenger ribonucleic acid levels in the rat pituitary.

Authors:  U B Kaiser; W W Chin
Journal:  J Clin Invest       Date:  1993-06       Impact factor: 14.808

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.